Sign in
Not yet taking people in United StatesNo phase

Wearable glucose sensor use after pregnancy with gestational diabetes

Looks at how women use a glucose sensor after gestational diabetes pregnancies.

Key facts

Who runs it
Oregon Health and Science University
Where
Philadelphia, Portland, and Santa Barbara, United StatesSee the 3 sites
Trial code
Registry title
Stelo Real-time Continuous Glucose Monitor Use Postpartum for Lifelong Optimal Wellness
Status
Not yet recruiting
People taking part
50 people, planned
Started
Jan 2026
Expected to end
Dec 2027
Type of study
Observational
Treatments tested
  • Dexcom Stelo real-time Continuous Glucose Monitor
Record updated
21 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women who recently gave birth and had gestational diabetes (diabetes during pregnancy) in their most recent pregnancy. They will use the Dexcom Stelo glucose sensor.

Age
18 Years and older
Sex
Female only
Disease stage
Gestational diabetes diagnosed during pregnancy by a 1- or 2-step Oral Glucose Tolerance Test, or a result of >= 200 mg after any glucose challenge (50g, 75g, 100g). Must be no more than 6 weeks and 6 days after giving birth. Must have a smartphone that works with the Dexcom Stelo app and read, write and understand English.
Earlier treatment
Cannot join if insulin was used before going home from the hospital stay for the birth. Cannot join after obesity surgery.

Main reasons for not taking part

  • Type 1 or type 2 diabetes before the pregnancy
  • Kidney failure needing dialysis, or heart failure
  • Large skin problems at the sensor sites, or severe allergy to medical adhesives
  • Insulin use before leaving the hospital after birth, or past obesity surgery
  • Taking part in another postpartum glucose monitoring or lifestyle trial

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Gestational Diabetes Mellitus (GDM) diagnosis by 1- or 2-step Oral Glucose Tolerance Test (OGTT) during pregnancy or >= 200 mg following any glucose challenge (50g, 75g, 100g)
  • Has a smart phone compatible to support Dexcom Stelo app
  • Able to read, write, and understand English
  • Meet Stelo Glucose Biosensor Indications for Use (IFU) per approved commercial labeling
  • Willing to follow all study procedures

Who cannot take part

  • Obesity surgery
  • Insulin use prior to discharge home from the delivery admission
  • Preexisting Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D)
  • End-stage renal failure (on dialysis)
  • Heart failure
  • Other uncontrolled high-risk condition as determined exclusionary by site investigators
  • Extensive skin changes/diseases that preclude wearing the required system on normal skin (e.g. extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis) at the proposed wear sites
  • Known severe allergy to medical-grade adhesives
  • Any condition that, in the opinion of the investigator, would interfere with their participation in the trial
  • Current participation in another postpartum Continuous Glucose Monitoring (CGM) or lifestyle intervention trial
  • Greater than 6 weeks and 6 days postpartum at enrollment

Where in United States

  • University of PennsylvaniaPhiladelphia, United StatesContact: Elizabeth NortonNot yet recruiting
  • Oregon Health Science UniversityPortland, United StatesContact: Christian Huertas PaganNot yet recruiting
  • Sansum Diabetes Research InstituteSanta Barbara, United StatesContact: Alex AlChwikani, Recruitment SpecialistNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this prospective observational study is to gather exploratory and practical use data of the Dexcom Stelo Glucose Biosensing System (Stelo), an over-the-counter (OTC) real-time Continuous Glucose Monitoring (CGM) system among patients with Gestational Diabetes Mellitus (GDM) in their most recent pregnancy.

The group in the trial

  • Postpartum Stelo Users

    Postpartum individuals with their most recent pregnancy complicated by Gestational Diabetes Mellitus (GDM)

    Treatment: Dexcom Stelo real-time Continuous Glucose Monitor

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Stelo Real-time Continuous Glucose Monitor Use Postpartum for Lifelong Optimal Wellness
Plain-language title
Wearable glucose sensor use after pregnancy with gestational diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
21 January 2026